Acquisition Pending

GSK acquisition of Nuvalent

US$11bn equity value

Announced 9 Jun 2026 · US$124.00 cash per share · 40% premium

Advisers

Nuvalent

Target

Financial adviser
Fairness opinion

GSK

Acquirer

Financial adviser
The Information Agent
Target
Nuvalent
Acquirer
GSK
Target based in
United States
Buyer based in
United Kingdom
Sector
Biotech
Tags
Biotech, Oncology, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.